Swiss Electrical Stock News

SWX:BKW
SWX:BKWElectric Utilities

BKW (SWX:BKW) Stock Margin Squeeze Clouds Its Low Carbon Buildout

BKW shareholders came into today already bruised, with the stock down about 14% over three months and closing at CHF128.30 just as the latest earnings landed. The immediate question is whether that slide reflects weakening profitability or a market that has fixated on the wrong part of the story. The key plot line in this earnings release is margin pressure. Net profit margin has slipped from 13.4% to 8.3%, while first half EBIT dropped to CHF262.7m even as net profit reached CHF217.6m and...
SWX:STMN
SWX:STMNMedical Equipment

Straumann Holding (SWX:STMN) Stock Rich Valuation Meets Profit Margin Compression

Straumann Holding stock closed at CHF97.22 on the day its latest figures landed, well below an internal discounted cash flow estimate of CHF160.06. The market has been trimming exposure in recent weeks; yet the fresh numbers highlight a different story. Earnings sit on a compressed 13.7% net profit margin after a CHF136.0m one off loss in the last twelve months, while the P/E of 43.5x prices Straumann as a premium dental equipment play. The key question for you is whether that margin squeeze...
SWX:GEBN
SWX:GEBNBuilding

Geberit (SWX:GEBN) Stock Commands A Premium After Margin Strength Holds

Geberit stock went into these results priced for quality plumbing perfection, trading on a rich 30.8x P/E and already up double digits over the past three months. The company then delivered what the thesis demands. Earnings grew over the last twelve months, margins stayed high with a 19.2% net profit margin, and management reaffirmed guidance for mid single digit sales and earnings growth. The twist for investors now is not whether Geberit is executing. Instead, it is whether this level of...
SWX:SIGN
SWX:SIGNPackaging

SIG Group (SWX:SIGN) Could Be 13% Below Fair Value Following CEO Shake Up

SIG Group (SWX:SIGN) abruptly replaced CEO Mikko Keto with former CFO Ann-Kristin Erkens less than six months into Keto’s tenure, raising questions about leadership stability despite reaffirmed guidance and an upcoming Capital Markets Day. See our latest analysis for SIG Group. For context, SIG Group’s 1 day share price return of 1.31% comes after a sharp 7 day share price decline of 14.20%. The 90 day share price return of 11.99% and year to date share price return of 14.92% contrast with a...
SWX:MED
SWX:MEDMedical Equipment

Medartis Holding (SWX:MED) Stock Can 18% EBITDA Margin Justify 78x P E

Medartis Holding stock has been on a tear, with a 3 month gain of about 22% heading into today, and the valuation now up at roughly 78x trailing P/E. The H1 2026 earnings print gave that optimism a fresh stress test. Revenue reached CHF 160.8m and the core EBITDA margin sat at 18%, which is the real headline. The market has been paying a rich multiple for growth and profitability, so this margin performance now becomes the key lens for both short term traders and long term holders. Love...
SWX:BSLN
SWX:BSLNBiotechs

Basilea Pharmaceutica (SWX:BSLN) Stock Rises With Profit Strength And Narrower Margins

Basilea Pharmaceutica stock closed at CHF62.50 on Wednesday after a strong run over the past month. Yet the real story sits in the earnings print that just landed. The headline is a cleaner, more profitable anti infectives business, with H1 2026 revenue of CHF118.996m translating into net income of CHF27.946m and basic earnings per share of CHF2.26. The market is reacting to a short burst of momentum. Long term holders are now weighing that profit profile against a modest growth outlook and a...
SWX:PSPN
SWX:PSPNReal Estate

PSP Swiss Property (SWX:PSPN) Stock Price Drifts As One Off Gains Cloud Earnings

PSP Swiss Property closed at CHF142.30 on Wednesday, capping a three month drift lower even as fresh Q2 numbers put eye catching profits on the table. The market reaction looks muted compared with the headline story. Net income excluding extra items reached CHF171.75m on CHF236.46m of revenue, helped by sizeable valuation gains and disposals that are hard to treat as everyday earnings power. That tension between a rich profit print today and softer multi year forecasts is the real hinge for...
SWX:PMN
SWX:PMNElectrical

Phoenix Mecano (SWX:PMN) Stock Looks Cheap After Margin Led Profit Jump

Phoenix Mecano stock closed at CHF443 today, only slightly above where it was trading a month ago, even after investors digested fresh half year numbers. The headline from these results is not the modest revenue move. It is the sharp jump in operating profitability, with earnings before interest and tax up 23.5% on the back of stronger margins in the industrial units. Over a longer horizon the story shifts to valuation. The stock trades on a trailing P/E of 14x, while peers sit much higher...
SWX:SKAN
SWX:SKANLife Sciences

SKAN Group (SWX:SKAN) Stock Richly Valued As Margin Recovery Lags Backlog Growth

SKAN Group stock has been on a tear into this earnings print, closing at CHF62.70 and logging a roughly 32% gain over the past three months. That kind of run sets a high bar for a specialised pharma equipment supplier. The headline from H1 is clear. SKAN Group delivered a sharp reset in profitability with net profit of CHF5.4m and an EBITDA margin of 9.3% on CHF164.5m of net sales. Order intake of CHF247.6m and a CHF442m backlog reflect why the growth story still commands a premium P/E...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN) Stock Looks Reasonable Despite Its 89% Five Year Run

Novartis stock has delivered a strong 88.5% return over the past five years, and the valuation checks now point to a company that looks undervalued on market multiples but not as a straightforward bargain across every metric. Over the past 5 years, Novartis has returned 88.5%, which puts recent short term ups and downs into the context of a solid multi year share price performance. Protecting cash flows from key products such as Entresto, supported by the recent UK court win on its patent,...
SWX:TECN
SWX:TECNLife Sciences

European Value Stocks Trading Below Estimated Fair Value

As European markets navigate the complexities of geopolitical tensions and fluctuating energy prices, the pan-European STOXX Europe 600 Index has seen a slight decline, reflecting mixed investor sentiment. In this environment, identifying stocks that are trading below their estimated fair value can offer opportunities for investors seeking to capitalize on resilient regional economic data and solid corporate earnings.
SWX:KUD
SWX:KUDElectronic

European Penny Stocks To Watch In August 2026

As the European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, investors are increasingly exploring diverse opportunities. Penny stocks, often seen as relics of past market eras, continue to offer intriguing potential for those willing to look beyond the larger indices. These smaller or newer companies can provide a unique mix of affordability and growth potential when paired with strong financials, making them an area worth watching for...
SWX:SKAN
SWX:SKANLife Sciences

SKAN Group (SWX:SKAN) Could Be 6% Undervalued On Its Return To Profit

SKAN Group (SWX:SKAN) has drawn fresh attention after reporting H1 2026 net income of CHF 4.81 million, compared with a net loss of CHF 8.9 million a year earlier. See our latest analysis for SKAN Group. The swing back to profit in H1 2026 has coincided with a clear shift in sentiment toward SKAN Group, with a 90 day share price return of 26.07% and a year to date gain of 13.03%, even though the 1 year total shareholder return is still down 11.66%. If SKAN Group’s rebound has you thinking...
SWX:SDZ
SWX:SDZPharmaceuticals

Did Sandoz’s Expanded Henlius Biosimilar Pact Just Redraw Its (SWX:SDZ) Investment Narrative?

Sandoz Group AG recently announced a collaboration agreement with Shanghai Henlius Biotech, Inc. to develop, manufacture and commercialise up to 10 biosimilars, including proposed versions of cetuximab, evolocumab and belimumab, with Henlius handling development and manufacturing and Sandoz holding commercial rights outside China under a milestones-based deal of up to US$322 million. This partnership lifts Sandoz’s biosimilar pipeline from 39 assets with potential to reach up to 46,...
SWX:ABBN
SWX:ABBNElectrical

Is ABB (SWX:ABBN) Fully Priced Following Its LevelTen Energy Deal?

Why ABB stock is drawing fresh attention after the LevelTen Energy deal ABB (SWX:ABBN) is back in focus after announcing a partnership and minority investment in LevelTen Energy, tying its electrification and energy management tools more tightly to global clean energy procurement. See our latest analysis for ABB. The LevelTen Energy announcement lands at a time when ABB's share price has gained clear momentum, with a 30 day share price return of 4.8% and a year to date share price return of...
SWX:SQN
SWX:SQNCapital Markets

Swissquote Stock And Other Trading Platforms Riding The Volatility Boom

With Michael Burry comparing the AI-fuelled rally to past bubbles and the CAPE ratio sitting close to its late 1999 peak, investors are watching a market where optimism and risk sit side by side. Trading venues and options infrastructure stocks can sit right in the slipstream of that activity. This article looks at three stocks exposed to the current news narrative and explains why their stories might deserve a place on your watchlist. The three stocks below are only a starting sample, and...
SWX:ALC
SWX:ALCMedical Equipment

Stronger Sales But Weaker Earnings Could Be A Game Changer For Alcon (SWX:ALC)

In the second quarter and first half of 2026, Alcon Inc. reported higher sales and revenue year on year, but net income for the six-month period fell to US$189 million from US$526 million, with basic and diluted earnings per share from continuing operations both dropping to US$0.39 from US$1.06. Even as Alcon maintained its full-year 2026 net sales growth guidance of 5% to 7%, the combination of rising revenue, lower profitability, and mixed valuation signals has sharpened investor focus on...
SWX:DOKA
SWX:DOKABuilding

3 Security Stocks Worth Watching As Demand For Better Protection Grows

Rising reports of violent homejackings around Lake Geneva are testing Switzerland’s image as a safe harbour for wealth, and that shift is drawing fresh attention to security and surveillance technology providers. When reputations and high end assets feel exposed, demand for better protection often moves quickly. This article walks through three stocks tied to these security themes and explains how the recent news could matter for their long term story. The stocks covered below are just a...
SWX:SCMN
SWX:SCMNTelecom

What Is Drawing Fresh Attention To Swisscom (SWX:SCMN)?

How Swisscom’s latest earnings update is shaping investor focus Swisscom (SWX:SCMN) drew fresh attention on 6 August 2026 after reporting half year results that combined lower sales of CHF 7,221 million with higher net income of CHF 669 million and basic EPS of CHF 12.92. See our latest analysis for Swisscom. Since the start of the year Swisscom’s share price has gained 10.36%, while the stock is down 5.47% over the past 90 days, and the 1 year total shareholder return of 14.85% points to...
SWX:GALD
SWX:GALDPharmaceuticals

Galderma Group (SWX:GALD) Wins EU Nod For Restylane Shaype, Is It Fully Priced?

Restylane Shaype launch puts Galderma Group in focus Galderma Group (SWX:GALD) has drawn fresh investor attention after securing European Union approval for Restylane Shaype, a hyaluronic acid gel designed specifically for minimally invasive chin shaping and augmentation. See our latest analysis for Galderma Group. The Restylane Shaype approval lands at a time when Galderma Group’s share price has eased in the very short term, with the 1 day and 7 day share price returns declining 3.11% and...
SWX:SREN
SWX:SRENInsurance

Swiss Re (SWX:SREN), Why Is Its Latest Update Drawing Attention?

Swiss Re (SWX:SREN) is drawing fresh attention after its H1 2026 results, with net income of US$2.831b and basic earnings per share of US$9.57 for the six months to June 30. See our latest analysis for Swiss Re. Swiss Re's share price has climbed over the past quarter, with a 90 day share price return of 14.82% and a year to date share price return of 7.15%. The 3 year total shareholder return of 93.41% highlights how long term holders have been rewarded, as recent earnings keep interest in...
SWX:KOMN
SWX:KOMNMachinery

Komax Holding (SWX:KOMN) Stock Price Trails Losses Despite Deep Value Gap

Komax Holding shares closed at CHF78.70 on Friday, only modestly higher over the past week and month, which suggests investors came into these results cautiously optimistic but not euphoric. The earnings headline is simple and uncomfortable. The wiring automation specialist is still loss making, with a basic earnings per share loss of CHF0.96 in the first half and trailing twelve month losses that remain in the mid single digit millions of francs. The key issue now is valuation. The stock...
SWX:ALC
SWX:ALCMedical Equipment

Is Alcon (SWX:ALC) Below Fair Value On Mixed Earnings And RxSight News?

Alcon (SWX:ALC) is back in focus after its second quarter 2026 earnings report. The results showed higher sales and revenue but a much lower net income figure, giving investors mixed signals to digest. See our latest analysis for Alcon. The recent earnings announcement, maintained 2026 net sales growth guidance, and the RxSight collaboration have come alongside a 90 day share price return of 17.97%, although the 1 year total shareholder return is down 13.93%. If this mix of earnings and...
SWX:ARYN
SWX:ARYNFood

ARYZTA (SWX:ARYN) Just Gave Investors Something To Reassess

ARYZTA (SWX:ARYN) has come into focus after reporting half year 2026 results that showed slightly lower sales and earnings. Investors are weighing what these updated figures mean for the stock. See our latest analysis for ARYZTA. ARYZTA's recent half year 2026 update comes after a tougher stretch for the stock, with the share price at CHF45.25 and the 30 day share price return down 18.32%. The 1 year total shareholder return is down 39.22%, which points to fading momentum as investors...